Because most physicians would be reluctant to prescribe anti–TNF-α therapy to patients with known or obvious active infections, we suspect that most extrapulmonary infections (primarily soft tissue infections) in our series likely developed in patients after they began anti–TNF-α therapy. This evidence concerns the gene TNF and infection.